$TDOC
Teladoc Health, Inc. Stock $tdoc

$tdoc Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000155837022002260 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$554.2M	$2.033B	$383.3M
YoY Change	44.6%	85.81%	144.94%
Cost Of Revenue	$175.0M	$650.3M	$122.9M
YoY Change	42.38%	66.38%	122.02%
Gross Profit	$379.3M	$1.382B	$260.4M
YoY Change	45.64%	96.61%	157.48%
Gross Profit Margin	68.43%	68.01%	67.94%
Selling, General & Admin	$290.9M	$688.6M	$531.7M
YoY Change	-45.28%	4.22%	768.32%
% of Gross Profit	76.71%	49.81%	204.19%
Research & Development	$72.87M	$311.9M	$92.70M
YoY Change	-21.39%	89.09%	470.6%
% of Gross Profit	19.21%	22.56%	35.6%
Depreciation & Amortization	$52.33M	$204.2M	$33.16M
YoY Change	57.82%	193.89%	199.01%
% of Gross Profit	13.8%	14.77%	12.73%
Operating Expenses	$416.1M	$1.000B	$661.4M
YoY Change	-37.08%	21.17%	753.65%
Operating Profit	-$36.87M	-$265.6M	-$401.0M
YoY Change	-90.81%	-47.55%	2472.49%
Interest Expense	-$18.87M	-$80.37M	-$20.80M
YoY Change	-9.27%	32.83%	173.68%
% of Operating Profit
Other Income/Expense, Net	-$405.0K	$5.088M
YoY Change		-1033.58%
Pretax Income	-$60.73M	-$384.7M	-$479.4M
YoY Change	-87.33%	-33.22%	1969.14%
Income Tax	-$49.74M	$44.14M	-$85.50M
% Of Pretax Income
Net Earnings	-$10.99M	-$428.8M	-$394.0M
YoY Change	-97.21%	-11.61%	1968.89%
Net Earnings / Revenue	-1.98%	-21.09%	-102.79%
Basic Earnings Per Share		-$2.73
Diluted Earnings Per Share	-$68.67K	-$2.73	-$3.064M
COMMON SHARES
Basic Shares Outstanding	160.1M	156.9M	145.0M
Diluted Shares Outstanding		156.9M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$896.0M	$896.0M	$786.6M
YoY Change	13.91%	13.85%	52.12%
Cash & Equivalents	$893.5M	$893.5M	$733.3M
Short-Term Investments	$2.537M	$2.537M	$53.25M
Other Short-Term Assets	$5.660M	$87.39M	$47.00M
YoY Change	-87.96%	85.93%	235.71%
Inventory	$73.08M	$73.08M	$56.50M
Prepaid Expenses	$38.26M
Receivables	$169.0M	$169.0M	$169.3M
Other Receivables	$21.17M	$0.00	$0.00
Total Short-Term Assets	$1.225B	$1.225B	$1.060B
YoY Change	15.65%	15.61%	80.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$27.23M	$74.01M	$28.55M
YoY Change	-4.61%	-1.31%	177.3%
Goodwill	$14.50B		$14.58B
YoY Change	-0.53%		1854.38%
Intangibles	$1.910B		$2.021B
YoY Change	-5.47%		796.36%
Long-Term Investments
YoY Change
Other Assets	$20.70M	$20.70M	$18.36M
YoY Change	12.78%	15.02%	180.47%
Total Long-Term Assets	$16.51B	$16.51B	$16.70B
YoY Change	-1.12%	-1.11%	1545.18%
TOTAL ASSETS
Total Short-Term Assets	$1.225B	$1.225B	$1.060B
Total Long-Term Assets	$16.51B	$16.51B	$16.70B
Total Assets	$17.73B	$17.73B	$17.76B
YoY Change	-0.12%	-0.11%	1007.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$47.26M	$47.26M	$46.03M
YoY Change	2.67%	2.73%	407.22%
Accrued Expenses	$162.0M	$162.0M	$156.0M
YoY Change	3.85%	3.85%	168.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$13.31M	$42.56M
YoY Change	-100.0%	-76.23%
Total Short-Term Liabilities	$331.0M	$331.0M	$332.6M
YoY Change	-0.49%	-0.6%	268.87%
LONG-TERM LIABILITIES
Long-Term Debt	$1.235B	$1.235B	$1.390B
YoY Change	-11.15%	-11.15%	215.91%
Other Long-Term Liabilities	$1.492M	$47.10M	$1.616M
YoY Change	-7.67%	0.21%	-82.51%
Total Long-Term Liabilities	$1.492M	$1.282B	$1.616M
YoY Change	-7.67%	-10.78%	-82.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$331.0M	$331.0M	$332.6M
Total Long-Term Liabilities	$1.492M	$1.282B	$1.616M
Total Liabilities	$332.5M	$1.689B	$334.3M
YoY Change	-0.53%	-9.74%	236.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.421B		-$992.7M
YoY Change	43.2%		95.59%
Common Stock	$17.47B		$16.86B
YoY Change	3.65%		995.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.05B	$16.05B	$15.88B
YoY Change
Total Liabilities & Shareholders Equity	$17.73B	$17.73B	$17.76B
YoY Change	-0.12%	-0.11%	1007.75%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$10.99M	-$428.8M	-$394.0M
YoY Change	-97.21%	-11.61%	1968.89%
Depreciation, Depletion And Amortization	$52.33M	$204.2M	$33.16M
YoY Change	57.82%	193.89%	199.01%
Cash From Operating Activities	$83.21M	$194.0M	-$114.9M
YoY Change	-172.39%	-462.52%	-734.33%
INVESTING ACTIVITIES
Capital Expenditures	-$22.92M	$8.534M	-$8.650M
YoY Change	164.98%	112.08%	155.16%
Acquisitions		$78.66M
YoY Change		-86.14%
Other Investing Activities	$2.846M	-$8.715M	-$405.3M
YoY Change	-100.7%		-3231.92%
Cash From Investing Activities	-$20.07M	-$72.98M	-$413.9M
YoY Change	-95.15%	-87.65%	-4438.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.625M	40.95M	70.44M
YoY Change	-90.59%	-95.23%	601.59%
NET CHANGE
Cash From Operating Activities	83.21M	194.0M	-114.9M
Cash From Investing Activities	-20.07M	-72.98M	-413.9M
Cash From Financing Activities	6.625M	40.95M	70.44M
Net Change In Cash	69.76M	162.0M	-458.4M
YoY Change	-115.22%	-24.55%	-1315.99%
FREE CASH FLOW
Cash From Operating Activities	$83.21M	$194.0M	-$114.9M
Capital Expenditures	-$22.92M	$8.534M	-$8.650M
Free Cash Flow	$106.1M	$185.5M	-$106.3M
YoY Change	-199.85%	-422.34%	-594.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	156939349
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90509229
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71844535
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.teladoc.com/20211231#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	156939000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90509000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71845000
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001477449
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	160469325
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	150281099
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.73
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.36
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.38
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.teladoc.com/20211231#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2020Q4	tdoc	Exercise Price Adjustment Ratio Closing Price Threshold Trading Days ExercisePriceAdjustmentRatioClosingPriceThresholdTradingDays	P4D
CY2020Q4	tdoc	Exercise Price Adjustment Ratio Closing Price Threshold Trading Days ExercisePriceAdjustmentRatioClosingPriceThresholdTradingDays	P4D
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-37477
CY2021	dei	Entity Registrant Name EntityRegistrantName	TELADOC HEALTH, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3705970
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Manhattanville Road
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 203
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Purchase
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	New York, New York
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	893480000
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10577
CY2021	dei	City Area Code CityAreaCode	203
CY2021	dei	Local Phone Number LocalPhoneNumber	635-2002
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	TDOC
CY2021	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	26317281887
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	160327041
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	733324000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	2537000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	53245000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	12384000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6412000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	168956000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	169281000
CY2021Q4	us-gaap	Inventory Net InventoryNet	73079000
CY2020Q4	us-gaap	Inventory Net InventoryNet	56498000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	87387000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	47259000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1225439000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1059607000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27234000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28551000
CY2021Q4	us-gaap	Goodwill Goodwill	14504174000
CY2020Q4	us-gaap	Goodwill Goodwill	14581255000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1910278000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2020864000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46780000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46647000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20703000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18357000
CY2021Q4	us-gaap	Assets Assets	17734608000
CY2020Q4	us-gaap	Assets Assets	17755281000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	47257000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	46030000
CY2021Q4	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	102933000
CY2020Q4	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	83657000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	91941000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	94593000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	75569000
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	52356000
CY2021Q4	tdoc	Advances From Financing Companies Current AdvancesFromFinancingCompaniesCurrent	13313000
CY2020Q4	tdoc	Advances From Financing Companies Current AdvancesFromFinancingCompaniesCurrent	13453000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	42560000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	331013000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	332649000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1492000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1616000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41773000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	43142000
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3834000
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2449000
CY2021Q4	tdoc	Advances From Financing Companies Noncurrent AdvancesFromFinancingCompaniesNoncurrent	9291000
CY2020Q4	tdoc	Advances From Financing Companies Noncurrent AdvancesFromFinancingCompaniesNoncurrent	9926000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	75777000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	102103000
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1225671000
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1379592000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	160469325
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150281099
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	160000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	150000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17473336000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	16857797000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1421454000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-992661000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6285000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	18518000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16045757000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	15883804000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17734608000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17755281000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2032707000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1093962000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	553307000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5284000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	650258000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	390829000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	184465000
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	416726000
CY2020	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	226146000
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	109697000
CY2021	us-gaap	Selling Expense SellingExpense	250581000
CY2020	us-gaap	Selling Expense SellingExpense	154052000
CY2019	us-gaap	Selling Expense SellingExpense	64915000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	311884000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	164941000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64644000
CY2021	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	26643000
CY2020	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	88236000
CY2019	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	6620000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	438007000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	506684000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	164456000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	204239000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	69495000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38952000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	2298338000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	1600383000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	633749000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-265631000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-506421000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-80442000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-43748000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-9077000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5088000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-545000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	342000
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-80365000
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-59950000
CY2019	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-29355000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-384656000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-575993000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-109455000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44137000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-90857000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10591000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-428793000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-485136000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	32000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-24803000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	35757000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4201000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-453596000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-449379000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-103033000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.73
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.36
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.38
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	156939349
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90509229
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71844535
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1013119000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	33275000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3380000
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	8000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	67276000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4169000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1014025000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54314000
CY2020	tdoc	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	-23705000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4722000
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	13884921000
CY2020	tdoc	Adjustments To Additional Paid In Capital Sale Of Capped Call Related To Livongo Notes AdjustmentsToAdditionalPaidInCapitalSaleOfCappedCallRelatedToLivongoNotes	91659000
CY2020	tdoc	Adjustments To Additional Paid In Capital Livongo Notes Guaranteed By Company AdjustmentsToAdditionalPaidInCapitalLivongoNotesGuaranteedByCompany	555448000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	478204000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	35757000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-485136000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	15883804000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25781000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	15331000
CY2021	tdoc	Recovered Excess Common Stock Issued For Acquisition Equity Impact RecoveredExcessCommonStockIssuedForAcquisitionEquityImpact	40329000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	315761000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-24803000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-428793000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16045757000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-428793000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-485136000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	204239000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	69495000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38952000
CY2021	tdoc	Depreciation Of Rental Equipment DepreciationOfRentalEquipment	3333000
CY2020	tdoc	Depreciation Of Rental Equipment DepreciationOfRentalEquipment	1697000
CY2019	tdoc	Depreciation Of Rental Equipment DepreciationOfRentalEquipment	0
CY2021	tdoc	Amortization Of Right Of Use Assets And Depreciation Of Rental Equipment AmortizationOfRightOfUseAssetsAndDepreciationOfRentalEquipment	12049000
CY2020	tdoc	Amortization Of Right Of Use Assets And Depreciation Of Rental Equipment AmortizationOfRightOfUseAssetsAndDepreciationOfRentalEquipment	6895000
CY2019	tdoc	Amortization Of Right Of Use Assets And Depreciation Of Rental Equipment AmortizationOfRightOfUseAssetsAndDepreciationOfRentalEquipment	6000000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	16941000
CY2020	tdoc	Accretion Of Interest AccretionOfInterest	45296000
CY2019	tdoc	Accretion Of Interest AccretionOfInterest	25438000
CY2021	tdoc	Gain Loss On Extinguishment Of Debt Cash Flow Impact GainLossOnExtinguishmentOfDebtCashFlowImpact	-40652000
CY2020	tdoc	Gain Loss On Extinguishment Of Debt Cash Flow Impact GainLossOnExtinguishmentOfDebtCashFlowImpact	-9077000
CY2019	tdoc	Gain Loss On Extinguishment Of Debt Cash Flow Impact GainLossOnExtinguishmentOfDebtCashFlowImpact	0
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	5901000
CY2020	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0
CY2019	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3845000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1009000
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1248000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17510000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21091000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15884000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	31090000
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2665000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	302586000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	475531000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	66702000
CY2021	tdoc	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	41800000
CY2020	tdoc	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-90158000
CY2019	tdoc	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-10868000
CY2021	tdoc	Accretion Of Interest AccretionOfInterest	61253000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12565000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2685000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19494000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	24732000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3547000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8135000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	105000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1188000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-87995000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	905000
CY2021	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	18175000
CY2020	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	20125000
CY2019	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	10026000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-4675000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	34819000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4546000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	20554000
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	17751000
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4815000
CY2021	tdoc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-16532000
CY2020	tdoc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-6300000
CY2019	tdoc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2417000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2607000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-2360000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-590975000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25013000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-605000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	193990000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53511000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	29869000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8534000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4024000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3510000
CY2021	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	55400000
CY2020	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	22018000
CY2019	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	7390000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	50000000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2496000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	52100000
CY2021	tdoc	Payments For Proceeds From Other Investments PaymentsForProceedsFromOtherInvestments	-10901000
CY2020	tdoc	Payments For Proceeds From Other Investments PaymentsForProceedsFromOtherInvestments	0
CY2019	tdoc	Payments For Proceeds From Other Investments PaymentsForProceedsFromOtherInvestments	5000000
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	78663000
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	567429000
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	11187000
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-8715000
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-72981000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	25781000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	54314000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	33283000
CY2021	tdoc	Proceeds From Sale Of Capped Call Related To Livongo Notes ProceedsFromSaleOfCappedCallRelatedToLivongoNotes	0
CY2020	tdoc	Proceeds From Sale Of Capped Call Related To Livongo Notes ProceedsFromSaleOfCappedCallRelatedToLivongoNotes	91659000
CY2019	tdoc	Proceeds From Sale Of Capped Call Related To Livongo Notes ProceedsFromSaleOfCappedCallRelatedToLivongoNotes	0
CY2021	tdoc	Proceeds From Advances From Financing Companies ProceedsFromAdvancesFromFinancingCompanies	15275000
CY2020	tdoc	Proceeds From Advances From Financing Companies ProceedsFromAdvancesFromFinancingCompanies	6002000
CY2019	tdoc	Proceeds From Advances From Financing Companies ProceedsFromAdvancesFromFinancingCompanies	0
CY2021	tdoc	Payments From Customers Against Advances From Financing Companies PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies	16050000
CY2020	tdoc	Payments From Customers Against Advances From Financing Companies PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies	8635000
CY2019	tdoc	Payments From Customers Against Advances From Financing Companies PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies	0
CY2021	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	0
CY2020	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	10000000
CY2019	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	0
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	16810000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	4722000
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	3380000
CY2021	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	3422000
CY2020	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	-26703000
CY2019	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	-1569000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-4152000
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40947000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	859136000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35094000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	161956000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	214650000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	89976000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1800000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4321000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	388000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	733324000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	514353000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	423989000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	893480000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	733324000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	514353000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3974000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1324000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1310000
CY2021	us-gaap	Interest Paid InterestPaid	16430000
CY2020	us-gaap	Interest Paid InterestPaid	14890000
CY2019	us-gaap	Interest Paid InterestPaid	12224000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Note 1. Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Teladoc, Inc. was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health” or the “Company”. The Company’s principal executive office is located in Purchase, New York. Teladoc Health is the global leader in whole person virtual care focused on forging a new healthcare experience with better convenience, outcomes and value around the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On October 30, 2020, the Company completed the merger with Livongo Health, Inc. (“Livongo”), a transformational opportunity to improve the delivery, access and experience of chronic healthcare for individuals around the world. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On July 1, 2020, the Company completed the acquisition of InTouch Technologies, Inc. (“InTouch”), a leading provider of enterprise telehealth solutions for hospitals and health systems.</p>
CY2021	tdoc	Number Of Professional Associations Consolidated As Variable Interest Entities NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities	3
CY2021	tdoc	Number Of Professional Corporations Consolidated As Variable Interest Entities NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities	12
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the Consolidated Statement of Operations, and if material, are also disclosed in the Notes to Consolidated Financial Statements. Significant estimates and assumptions by management affect areas including the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the useful life of intangible assets, the capitalization and amortization of software development costs, deferred costs, and the accounting for business combinations. Other significant areas include revenue recognition (including Client performance guarantees), the accounting for income taxes, contingencies, litigation and related legal accruals, and the accounting for stock-based compensation awards.</p>
CY2021	tdoc	Contract With Customer Term ContractWithCustomerTerm	P1Y
CY2021	tdoc	Payment Terms PaymentTerms	P30D
CY2021	tdoc	Contract With Customer Refunds Issued ContractWithCustomerRefundsIssued	26000000.0
CY2020	tdoc	Contract With Customer Refunds Issued ContractWithCustomerRefundsIssued	11200000
CY2019	tdoc	Contract With Customer Refunds Issued ContractWithCustomerRefundsIssued	3600000
CY2021	tdoc	Contract With Customer Liability Increase Decrease For Change In Estimate Of Transaction Price And Change In Client Performance Guarantees ContractWithCustomerLiabilityIncreaseDecreaseForChangeInEstimateOfTransactionPriceAndChangeInClientPerformanceGuarantees	5600000
CY2020	tdoc	Contract With Customer Liability Increase Decrease For Change In Estimate Of Transaction Price And Change In Client Performance Guarantees ContractWithCustomerLiabilityIncreaseDecreaseForChangeInEstimateOfTransactionPriceAndChangeInClientPerformanceGuarantees	1900000
CY2019	tdoc	Contract With Customer Liability Increase Decrease For Change In Estimate Of Transaction Price And Change In Client Performance Guarantees ContractWithCustomerLiabilityIncreaseDecreaseForChangeInEstimateOfTransactionPriceAndChangeInClientPerformanceGuarantees	800000
CY2021	tdoc	Amortization Term Of Deferred Contract Cost AmortizationTermOfDeferredContractCost	P4Y
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	205300000
CY2020	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	110800000
CY2019	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	23600000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	893500000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	110800000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	335800000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	297000000.0
CY2020	us-gaap	Advertising Expense AdvertisingExpense	165000000.0
CY2019	us-gaap	Advertising Expense AdvertisingExpense	88800000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Risk </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and accounts receivable. Although the Company deposits its cash with multiple financial institutions in the U.S. and in foreign countries, its deposits, at times, may exceed federally insured limits. The Company’s short-term investments are comprised of a portfolio of diverse high credit rating instruments with maturity durations of one year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">No Client represented over 10% of revenues for the years ended December 31, 2021, 2020, or 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">No Client represented over 10% of accounts receivable at December 31, 2021 or 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Revenue from Clients located in the United States for the year ended December 31, 2021, 2020, and 2019 were $1,774.0 million, $913.7 million and $423.3 million, respectively. Revenue from Clients located outside the United States for the year ended December 31, 2021, 2020 and 2019 were $258.7 million, $180.2 million, and $130.0 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;"></span></p>
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Certain prior year amounts have been reclassified to conform to the current year presentation.</p>
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2032707000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1093962000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	553307000
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	79400000
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	54800000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	24600000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	40000000
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	51000000.0
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	12500000
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	73100000
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3100000
CY2021Q4	tdoc	Deferred Device Cost And Other Current DeferredDeviceCostAndOtherCurrent	22304000
CY2020Q4	tdoc	Deferred Device Cost And Other Current DeferredDeviceCostAndOtherCurrent	3468000
CY2021Q4	tdoc	Deferred Device Cost And Other Noncurrent DeferredDeviceCostAndOtherNoncurrent	6249000
CY2020Q4	tdoc	Deferred Device Cost And Other Noncurrent DeferredDeviceCostAndOtherNoncurrent	2179000
CY2021Q4	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	28553000
CY2020Q4	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	5647000
CY2020Q4	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	5647000
CY2021	tdoc	Deferred Device Cost And Other Additions DeferredDeviceCostAndOtherAdditions	41579000
CY2021	tdoc	Deferred Device Cost And Other Cost Of Revenue Recognized DeferredDeviceCostAndOtherCostOfRevenueRecognized	-18673000
CY2021Q4	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	28553000
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5000000
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	5901000
CY2021	tdoc	Equity Securities Without Readily Determinable Fair Value Sale Of Investment EquitySecuritiesWithoutReadilyDeterminableFairValueSaleOfInvestment	10901000
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	0
CY2021Q4	us-gaap	Inventory Raw Materials And Purchased Parts Net Of Reserves InventoryRawMaterialsAndPurchasedPartsNetOfReserves	26164000
CY2020Q4	us-gaap	Inventory Raw Materials And Purchased Parts Net Of Reserves InventoryRawMaterialsAndPurchasedPartsNetOfReserves	19591000
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	313000
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1431000
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	46602000
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	35476000
CY2021Q4	us-gaap	Inventory Net InventoryNet	73079000
CY2020Q4	us-gaap	Inventory Net InventoryNet	56498000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	61364000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	50516000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34130000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21965000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27234000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28551000
CY2021	us-gaap	Depreciation Depreciation	8900000
CY2020	us-gaap	Depreciation Depreciation	4800000
CY2019	us-gaap	Depreciation Depreciation	3400000
CY2021Q4	tdoc	Capitalized Cloud Computing Implementation Costs Included In Other Assets CapitalizedCloudComputingImplementationCostsIncludedInOtherAssets	2400000
CY2020Q4	tdoc	Capitalized Cloud Computing Implementation Costs Included In Other Assets CapitalizedCloudComputingImplementationCostsIncludedInOtherAssets	0
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2266943000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	356665000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1910278000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2183399000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	162535000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2020864000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	195300000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	64700000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	35600000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	206602000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	210494000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	205595000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	181729000
CY2021Q4	tdoc	Finite Lived Intangible Assets Amortization Expense Year Five And Thereafter FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter	1105858000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1910278000
CY2020Q4	us-gaap	Goodwill Goodwill	14581255000
CY2019Q4	us-gaap	Goodwill Goodwill	746079000
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	64269000
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	13812198000
CY2021	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-55801000
CY2020	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	0
CY2021	tdoc	Goodwill Measurement Period Adjustment Deferred Taxes GoodwillMeasurementPeriodAdjustmentDeferredTaxes	-66505000
CY2020	tdoc	Goodwill Measurement Period Adjustment Deferred Taxes GoodwillMeasurementPeriodAdjustmentDeferredTaxes	0
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-19044000
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	22978000
CY2021Q4	us-gaap	Goodwill Goodwill	14504174000
CY2020Q4	us-gaap	Goodwill Goodwill	14581255000
CY2019	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2021Q4	tdoc	Percentage Of Increase In Fair Value From Carrying Value PercentageOfIncreaseInFairValueFromCarryingValue	0.15
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5373000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4717000
CY2021Q4	tdoc	Accrued Consulting And Customer Service Fees Current AccruedConsultingAndCustomerServiceFeesCurrent	19292000
CY2020Q4	tdoc	Accrued Consulting And Customer Service Fees Current AccruedConsultingAndCustomerServiceFeesCurrent	23167000
CY2021Q4	tdoc	Other Current Liabilities Clients Guarantees OtherCurrentLiabilitiesClientsGuarantees	7653000
CY2020Q4	tdoc	Other Current Liabilities Clients Guarantees OtherCurrentLiabilitiesClientsGuarantees	7215000
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1480000
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2049000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3098000
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1627000
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	3884000
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	3139000
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3471000
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2815000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12687000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11438000
CY2020Q4	tdoc	Accrued Earn Out Current AccruedEarnOutCurrent	4514000
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	9965000
CY2020Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2099000
CY2021Q4	tdoc	Other Current Liabilities Device Replacement Cost OtherCurrentLiabilitiesDeviceReplacementCost	6263000
CY2020Q4	tdoc	Other Current Liabilities Device Replacement Cost OtherCurrentLiabilitiesDeviceReplacementCost	0
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	29767000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	20877000
CY2021Q4	tdoc	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	102933000
CY2020Q4	tdoc	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	83657000
CY2021Q4	tdoc	Advances From Financing Companies Customer Payments Due Year One AdvancesFromFinancingCompaniesCustomerPaymentsDueYearOne	13313000
CY2021Q4	tdoc	Advances From Financing Companies Customer Payments Due Year Two AdvancesFromFinancingCompaniesCustomerPaymentsDueYearTwo	7153000
CY2021Q4	tdoc	Advances From Financing Companies Customer Payments Due Year Three AdvancesFromFinancingCompaniesCustomerPaymentsDueYearThree	2138000
CY2021Q4	tdoc	Advances From Financing Companies Customer Payments Due AdvancesFromFinancingCompaniesCustomerPaymentsDue	22604000
CY2021	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	14087000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1087000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	3000
CY2021	us-gaap	Lease Cost LeaseCost	15177000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	14531000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11598000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M15D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0588
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15021000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	14981000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	9871000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7232000
CY2021Q4	tdoc	Lessee Operating Lease Liability Payments Due Year Five And After Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive	18659000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	65764000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11304000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	54460000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	302586000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	475531000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66702000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-365762000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-566266000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-95476000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-18894000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-9727000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13979000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-384656000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-575993000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-109455000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-1954000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	239000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	567000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	27000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	300000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2595000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1605000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-262000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3162000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-322000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	277000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	49008000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-60008000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5043000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-6276000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-26775000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1783000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1757000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3752000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-4042000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	40975000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-90535000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10868000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44137000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-90857000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10591000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.077
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.023
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.046
CY2021	tdoc	Effective Income Tax Rate Reconciliation Acquisition Expenses EffectiveIncomeTaxRateReconciliationAcquisitionExpenses	0.020
CY2020	tdoc	Effective Income Tax Rate Reconciliation Acquisition Expenses EffectiveIncomeTaxRateReconciliationAcquisitionExpenses	-0.022
CY2019	tdoc	Effective Income Tax Rate Reconciliation Acquisition Expenses EffectiveIncomeTaxRateReconciliationAcquisitionExpenses	-0.004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.067
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.011
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.077
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.002
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.022
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.469
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.054
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.253
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.017
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.115
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.158
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.097
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	687679000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	497603000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	5413000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	7016000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	63641000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	94029000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	4814000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	5727000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1320000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	14666000
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	56000
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	83000
CY2021Q4	tdoc	Deferred Tax Assets Interest Expenses Carryforward DeferredTaxAssetsInterestExpensesCarryforward	11528000
CY2020Q4	tdoc	Deferred Tax Assets Interest Expenses Carryforward DeferredTaxAssetsInterestExpensesCarryforward	6620000
CY2021Q4	tdoc	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	13575000
CY2020Q4	tdoc	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	13978000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	7946000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2917000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7032000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3290000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	803004000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	645929000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	335810000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	107984000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	467194000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	537945000
CY2021Q4	tdoc	Deferred Tax Liabilities Debt Restructure Costs DeferredTaxLiabilitiesDebtRestructureCosts	73378000
CY2020Q4	tdoc	Deferred Tax Liabilities Debt Restructure Costs DeferredTaxLiabilitiesDebtRestructureCosts	105063000
CY2021Q4	tdoc	Deferred Tax Liabilities Operating Lease Liabilities DeferredTaxLiabilitiesOperatingLeaseLiabilities	11842000
CY2020Q4	tdoc	Deferred Tax Liabilities Operating Lease Liabilities DeferredTaxLiabilitiesOperatingLeaseLiabilities	12117000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3427000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2476000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	452049000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	519397000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2275000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	995000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	542971000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	640048000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	75777000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	102103000
CY2021Q4	tdoc	Operating Loss Carryforwards Not Subject To Expiration OperatingLossCarryforwardsNotSubjectToExpiration	2219800000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	335800000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	227900000
CY2021	tdoc	Valuation Allowance Deferred Tax Asset Purchase Accounting Adjustments Increase Decrease Amount ValuationAllowanceDeferredTaxAssetPurchaseAccountingAdjustmentsIncreaseDecreaseAmount	48500000
CY2021	tdoc	Valuation Allowance Deferred Tax Asset Current Year Tax Expense Increase Decrease Amount ValuationAllowanceDeferredTaxAssetCurrentYearTaxExpenseIncreaseDecreaseAmount	179400000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21362000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Acquisition UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition	59110000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	43399000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1490000
CY2021	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-14513000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	110848000
CY2021Q4	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	110800000
CY2021Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	7300000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-428793000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-485136000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	156939000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90509000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71845000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.73
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.36
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.38
CY2021	tdoc	Minimum Age Of Employee Eligible Under Plan MinimumAgeOfEmployeeEligibleUnderPlan	P21Y
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	300000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	11300000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4900000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3200000

Files In Submission

Name	View Source	Status
0001558370-22-002260-index-headers.html	Edgar Link	pending
0001558370-22-002260-index.html	Edgar Link	pending
0001558370-22-002260.txt	Edgar Link	pending
0001558370-22-002260-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tdoc-20211231.xsd	Edgar Link	pending
tdoc-20211231x10k.htm	Edgar Link	pending
tdoc-20211231x10k004.jpg	Edgar Link	pending
tdoc-20211231x10k_htm.xml	Edgar Link	completed
tdoc-20211231xex21d1.htm	Edgar Link	pending
tdoc-20211231xex23d1.htm	Edgar Link	pending
tdoc-20211231xex31d1.htm	Edgar Link	pending
tdoc-20211231xex31d2.htm	Edgar Link	pending
tdoc-20211231xex32d1.htm	Edgar Link	pending
tdoc-20211231xex32d2.htm	Edgar Link	pending
tdoc-20211231_cal.xml	Edgar Link	unprocessable
tdoc-20211231_def.xml	Edgar Link	unprocessable
tdoc-20211231_lab.xml	Edgar Link	unprocessable
tdoc-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TDOC
Teladoc Health, Inc. Stock $tdoc

2021 Q4 Form 10-K Financial Statement

#000155837022002260 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TDOC Teladoc Health, Inc. Stock $tdoc

2021 Q4 Form 10-K Financial Statement

#000155837022002260 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TDOC
Teladoc Health, Inc. Stock $tdoc